The immunosuppressive pipeline: Meeting unmet needs in liver transplantation
Nazia Selzner, David R. Grant, Itay Shalev, Gary A. Levy – 28 September 2010 – Liver transplantation is now recognized as the treatment of choice for end‐stage liver failure. Its success can be attributed largely to the generation of selective immunosuppressive agents, which have resulted in a dramatic reduction in the incidence of acute rejection and improvements in the short‐ and long‐term outcomes of patients.